DGX - Educational Analysis * US Equities
Educational Analysis * US Equities

DGX

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerDGX
CategoryEducational primer
Last reviewedNovember 17, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Quest Diagnostics Incorporated is classified in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. The company’s core Diagnostic Information Services segment turns laboratory testing into clinical insights for patients, physicians, and organizations, while its smaller Diagnostic Solutions segment supplies risk-assessment services to insurers and healthcare-IT solutions to providers and payers.

Scale is the most visible feature of the franchise. In 2025 Quest generated $11.0 billion in net revenues and processed approximately 244 million test requisitions. It serves roughly one-third of U.S. adults annually, along with about half of U.S. physicians and half of U.S. hospitals each year. Operationally, it runs approximately 2,400 patient service centers, roughly 8,000 patient access points, and a logistics network making more than 83,000 stops every day.

The financial returns support the idea of a durable but not exceptionally wide moat. Net margin is 9.5% and return on equity is 15.2%. A 9.5% net margin is healthy for a high-volume services business, yet it also indicates that pricing power is constrained by payer contracts, Medicare reimbursement schedules, and routine lab commoditization. The 15.2% ROE shows that management converts equity into profit efficiently. Taken together, the numbers point to a competitively entrenched, asset-heavy network whose advantage comes from reach, volume, and logistics density rather than extraordinary margins.

Financial posture

Quest currently carries a market capitalization of $28.8 billion and trades at a P/E of 25.8. Against a net margin of 9.5% and ROE of 15.2%, that multiple reads as a stability premium rather than a deep-value valuation. Investors are effectively paying for predictable cash flows and low correlation with the broader equity market, reflected in a beta of 0.55.

The low beta implies that Quest’s shares historically move roughly half as much as the broader market in either direction, consistent with non-discretionary demand for diagnostic testing. The 25.8 P/E, meanwhile, prices in both that defensive quality and the company’s ability to compound equity at a mid-teens ROE. With $11.0 billion in annual revenue behind the $28.8 billion equity value, the valuation is anchored to the company’s status as a large-scale provider of recurring healthcare services rather than to blockbuster growth.

Strategic priorities & outlook

Quest’s most recent 10-K filing outlines four operational priorities. The first is revenue growth through an industry-leading test menu and deeper collaboration with healthcare providers and partners, leveraging broad physical access. The second is growth through value-creating, strategically aligned acquisitions that are filtered through disciplined investment criteria. The third is monetizing data assets and services to improve population health and enable value-based care arrangements. The fourth is optimizing operating efficiency through the Quest Management System, automation, artificial intelligence, and the Invigorate cost-excellence program.

These priorities map cleanly onto the company’s reported footprint and returns. The 2,400 patient service centers and 8,000 access points provide the distribution base for a wider test menu, while the $11.0 billion revenue base and 244 million annual requisitions generate the data pools the company wants to commercialize. If cost initiatives such as Invigorate and automation can protect or expand the 9.5% net margin while volume grows, the 15.2% ROE can be sustained without relying on aggressive leverage.

Macro & geopolitical exposure

As a Medical - Diagnostics & Research company, Quest’s macro profile is dominated by domestic healthcare policy and regulation rather than by trade or commodity cycles. Reimbursement rates under Medicare, Medicaid, and commercial insurance contracts directly affect revenue per test and, by extension, the 9.5% net margin. Any legislative or administrative change to lab fee schedules is therefore a top-line risk.

Regulatory oversight of laboratory-developed tests and broader FDA policy also matter for the industry. Diagnostic labs depend on reagent and equipment supply chains, so shortages or price spikes in testing consumables can pressure costs. Labor availability for phlebotomists, lab technicians, and logistics staff affects network capacity. Currency exposure is comparatively modest because Quest’s operations are U.S.-centric, but demand can fluctuate with public-health cycles. In short, the primary exposures are reimbursement, regulation, supply-chain input costs, and healthcare labor availability.

Recent developments

Between November 9 and November 12, 2026, Quest was in front of investors several times. On November 12, 2026, Zacks.com published “Here’s Why Quest Diagnostics (DGX) is a Strong Value Stock,” adding to the valuation discussion around the stock. On November 10, 2026, PR Newswire reported that Quest Diagnostics declared its quarterly cash dividend. The headline did not include a per-share dividend amount in the data provided, but the announcement itself continues the company’s practice of returning cash to shareholders.

On November 9, 2026, the company announced appearances at two separate conferences: the 9th Annual Evercore Healthcare Conference and the Jefferies Global Healthcare Conference in London, both reported via PR Newswire. These events put management in front of institutional investors but did not disclose specific forward guidance in the headline summaries.

Earnings behavior & post-earnings drift

Quest has delivered a perfect beat rate over the last eight reported quarters: 8 out of 8, or 100%. The average earnings surprise across that span is 4.2%. Despite the consistency, the average 5-day price move after earnings is only 0.36%, classified as “flat.” This is the central post-earnings pattern: the company reliably exceeds the official consensus, but the market rarely rewards those beats with a sustained directional move.

The most recent four quarters illustrate the dynamic. On October 22, 2026, Quest reported EPS of $3.00 against an estimate of $2.87, a 4.5% surprise, yet the stock fell 0.57% the next day and gained 3.96% over the following five days. On July 23, 2026, EPS came in at $3.12 versus $2.82, a 10.6% surprise, with the next-day move essentially flat at -0.02% and a 2.81% gain over five days. On April 21, 2026, EPS of $2.50 beat the $2.37 estimate by 5.5%, but the stock dropped 0.51% the next day and fell 4.87% over five days. On February 10, 2026, EPS of $2.42 edged past the $2.36 estimate by 2.5%, producing a 1.93% next-day pop but a -0.47% five-day drift.

Across those reports, larger surprises did not guarantee larger gains, and the immediate next-day reaction was sometimes negative. The next scheduled release is February 9, 2027, before the market opens, with a current consensus EPS estimate of $2.68. As of the latest snapshot, the stock traded at $262.21, with a 50-day EMA of $243.85 and an RSI of 71.6.

Frequently Asked Questions

What does Quest's 100% earnings beat rate over the last eight quarters mean for traders?

It means Quest has beaten the official EPS estimate in every one of the last eight reported quarters, with an average surprise of 4.2%. However, the average 5-day post-earnings drift is only 0.36%, classified as flat, so consistent beats have not translated into a reliable directional pop.

What strategic priorities does Quest emphasize in its 10-K?

The company focuses on growing through an industry-leading test menu and provider collaboration, making disciplined acquisitions, using data assets to support population health and value-based care, and improving efficiency through automation, AI, and the Invigorate cost program.

Which macro factors most affect a Medical - Diagnostics & Research firm like Quest?

The main exposures are reimbursement rates from Medicare, Medicaid, and commercial payers; regulatory changes affecting laboratory testing; supply-chain and reagent costs; and labor availability for phlebotomy, lab, and logistics roles. Currency and commodity exposure are comparatively limited.

For a deeper dive into how institutional analysts weigh these fundamentals against the current valuation, review the full institutional verdict on the ticker.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 17, 2026
Quest Diagnostics Incorporated · Healthcare / Medical - Diagnostics & Research
$28.8BMarket cap
25.8P/E
9.5%Net margin
15.2%ROE
100%Beat rate, last 8Q
4.2%Avg EPS surprise
0.36%Avg 5-day move after earnings
2027-02-09Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-10-22$3$2.87+4.5%-0.57%+3.96%
2026-07-23$3.12$2.82+10.6%-0.02%+2.81%
2026-04-21$2.5$2.37+5.5%-0.51%-4.87%
2026-02-10$2.42$2.36+2.5%+1.93%-0.47%
2025-10-21$2.6$2.5+4%--
2025-07-22$2.62$2.57+1.9%--

Previous DGX editions

Beyond the primer

Get the institutional verdict on DGX

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the DGX verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.